Dr. Eric J. Grigsby
Dr. Eric Grigsby, MD, MBA has devoted his life to advancing the diagnosis and treatment of chronic pain. In 1992, Dr. Eric Grigsby founded the Napa Pain Institute. Over 25 years later, he has grown a single, small clinic into Neurovations- a national patient care, and innovation company that includes medical device and pharmaceutical innovation, clinical research, pain and neuroscience education, and community health through the non-profit Foundation, HealthRoots.
Dr. Grigsby attended elementary and secondary school in his hometown of Knoxville, Tennessee, and received a Bachelor's Degree in Biology and Economics from Brown University in Providence, Rhode Island. He formed an interest in Pain Management as a career while working at Boston Children’s Hospital in the Department of Orthopedic Surgery.
After graduating from Boston University Medical School in 1984, Dr. Grigsby trained in General Surgery, Anesthesiology, and Pain Management at the Mayo Clinic in Rochester, Minnesota. He was then invited to join the Medical Staff and teach at the Mayo Medical School. He moved to California in 1989 where he established the pain management center at UC Davis and served as Medical Director until 1992. Following his post at UC Davis, Dr. Grigsby established Napa Pain Institute in Napa, California.
Dr. Grigsby completed his Masters in Business Administration from Duke University’s Fuqua School of Business and has provided consultation in market analysis, strategic positioning, sales, product development, and physician training for industry leaders and early-stage companies. Dr. Grigsby speaks nationally on topics including neuromodulation, non-operative treatment of spinal disorders, the safe use of medications for treatment of pain, and the legal and regulatory issues relating to the proper treatment of patients with chronic illness.
Dr. Grigsby continues to practice as a board-certified Pain Physician and is among the world’s clinical leaders in the field of neuromodulation. As CEO and Founder of Neurovations, his unwavering mission is to inspire hope and to contribute to the health and well-being of patients and communities through integrated clinical practice, research, and education.
Dr. Steve Collins
As a distinguished leader in pharmaceutical R&D, Dr. Collins has held senior roles in various pharmaceutical and biotech companies across diverse therapeutic areas, resulting in the approval of over a dozen drugs and devices. Currently, he serves as the Executive Chairman of Vetana Animal Health, Inc., a biologics-focused company specializing in anti-inflammatory solutions. He is also on the Board of Directors for Xalud Therapeutics, a biologics-based therapy platform, and Cerebral Therapeutics, Inc., a drug-delivery platform for neurological diseases.
Previously, Dr. Collins was the President and CEO of Biscayne Neurotherapeutics, which was acquired by Supernus Pharmaceuticals. He also led NeuroTherapeutics Pharma, where he secured $42 million in funding for CNS therapeutics. His industry experience includes roles at Spinifex Pharmaceuticals (acquired by Novartis), Ovation Pharmaceuticals (acquired by Lundbeck A/S), Johnson & Johnson, and Abbott Laboratories.
Before transitioning to the industry, Dr. Collins held academic positions at Case Western Reserve University and the University of California-San Francisco. He conducted extensive research and clinical trials, contributing to the development of various drugs and devices. Dr. Collins holds MD and PhD degrees from Case Western Reserve University, with an undergraduate background in Physics from the University of California, Berkeley.